Tenderwize
Retour à la recherche

Pharmaceutical products with active ingredients Glecaprevir and Pibrentasvir (ATC: J05AP57)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Apr 29, 2027 · 244 days left·Open·Supplies
Titre original de l'avis

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Glecaprevir und Pibrentasvir (ATC: J05AP57)

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

No estimated contract value, budget, or framework maximum is provided, making it impossible to assess financial opportu...

The contract can be terminated if the buyer launches exclusive tenders for the same active ingredients during the contr...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Entering into non-exclusive discount agreements for pharmaceutical products containing Glecaprevir and Pibrentasvir
  • Open-house model: any qualified pharmaceutical company can join at any time
Afficher le résumé complet

Non-exclusive discount contract opportunity under an 'open-house model' for pharmaceutical products containing Glecaprevir and Pibrentasvir (ATC: J05AP57), issued by AOK Sachsen-Anhalt. Qualified pharmaceutical companies can enter into contracts at any time until 30 April 2027. The contract runs for a maximum of 24 months until 30 June 2027. No estimated value is provided. The notice clarifies it is not a public procurement under GWB but is published for transparency.

Risques

No estimated contract value, budget, or framework maximum is provided, making it impossible to assess financial opportu...

The contract can be terminated if the buyer launches exclusive tenders for the same active ingredients during the contr...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company or consortium of pharmaceutical companies

Administrative

  • Request participation documents from the contact address
  • Complete and sign the participation documents

Acheteur

Localisation

Magdeburg, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE258393558

Activité

Health

Lots (1)

LOT-0001

Pharmaceutical products with active ingredients Glecaprevir and Pibrentasvir (ATC: J05AP57)

Non-exclusive discount agreements for finished medicinal products with the active ingredients Glecaprevir and Pibrentasvir. Any eligible pharmaceutical company can join at any time under uniform conditions. The contract duration is up to 24 months from 1 July 2025 to 30 June 2027. The contract may be terminated early if the buyer launches exclusive tenders for the same active ingredients.

SuppliesEU fundedElectronic submission

Localisation

DEE03, Germany

Durée

2 YEAR

Catégorie

Pharmaceutical products

Date limite

Deadline Apr 29, 2027

Détails de la procédure

Date de publication
18 May 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
318621-2025

Documents (1)

Appels d'offres similaires